Business Context and Reporting Period
This Form 8-K is filed by Eyenovia, Inc. (not Hyperion DeFi, Inc.) on August 13, 2018. The registrant is a Delaware corporation focused on ophthalmic therapeutics. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding clinical trial results.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The primary material change reported is the announcement of positive results from the EYN PG21 proof-of-concept study. The study evaluated microdose latanoprost for lowering intraocular pressure and assessed patient usability.
Guidance, Outlook, and Risks
- Management Commentary: The company issued a press release (Exhibit 99.1) confirming positive outcomes for the EYN PG21 study.
- Legal Disclaimer: The information in Item 7.01 and the attached press release is furnished and not deemed "filed" under Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
- Risks/Contingencies: No specific financial risks or contingencies are detailed in this text, though clinical trial outcomes inherently carry development risks.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific clinical data points.
- Confirm the registrant name is Eyenovia, Inc. (the input metadata listed "Hyperion DeFi, Inc." which is incorrect based on the filing text).
- Review subsequent filings for any financial impact or updated guidance resulting from the EYN PG21 study results.
- Check the company's latest 10-Q or 10-K for current liquidity and cash position, as this 8-K does not provide them.